Trial Profile
A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms Harmony Outcomes
- Sponsors GlaxoSmithKline; GSK
- 19 Jul 2021 Results published in the Trials
- 02 Oct 2018 Primary endpoint (Time to first occurrence of MACE (cardiovascular death, myocardial infarction, or stroke) [Non-inferiority]) has been met, according to the results published in The Lancet.
- 02 Oct 2018 Results published in The Lancet.